A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Heart disease is more common in people over 65, but treatments are better than ever. That can complicate decision-making for ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...